

Emcure Q3 Net Jumps 30% to ₹156 crore

Our Bureau

Mumbai: Emcure Pharmaceuticals on Thursday reported a 30.3% year-on-year (YoY) rise in net profit in the quarter to December, led by strong performance of domestic and international business.

The Pune-based drug maker said net profit rose to ₹156 crore from ₹120 crore in the year-ago quarter. On a quarter-on-quarter basis, though, net profit dropped 22.6%



Revenue grew 17.7% YoY to ₹1,963 crore in the quarter under review, up from ₹1,668 crore in the year-ago quarter.

“Our international business is seeing strong performance on back of our differentiated product portfolio, on the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portfolio,” said Satish Mehta, CEO and managing director, Emcure.

Ebitda rose 23.2% YoY to ₹362 crore crore, while Ebitda margin rose 80 basis points YoY to 18.4%.